A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS 6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy
A study on the effect of study drug GS 6615 on exercise capacity in patients Hypertrophic Cardiomyopathy HCM
Sponsor: Gilead
Enrolling: Male and Female Patients
IRB Number: AAAP8359
U.S. Govt. ID: NCT02291237
Contact: Mary Marks: 212-305-1429 / mc2228@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if study drug GS-6615 improves the symptoms of Hypertrophic Cardiomyopathy (HCM) and helps the heart work better. HCM is a disease that affects the muscle of the heart. HCM is a condition in which the heart muscle becomes abnormally thick for no clear reason. This can make it harder for blood to enter and leave the heart, forcing the heart to work harder to pump blood.
This study is closed
Investigator
Mathew Maurer, MD
Do You Qualify?
Do you have coronary artery disease? Yes No
Have you been diagnosed with Hypertrophic Cardiomyopathy (HCM)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Mary Marks
mc2228@cumc.columbia.edu
212-305-1429
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE